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Abstract 
Background: The PD COMM pilot randomised controlled trial compared Lee Silverman Voice Treatment (LSVT® 
LOUD) with standard NHS speech and language therapy (SLT) and a control arm in people with Parkinson’s disease 
(PwPD) with self-reported problems with voice or speech. This analysis compares costs and quality of life outcomes 
between the trial arms, and considers the validity of the alternative outcome measures for economic evaluations.
Methods: A comparison of costs and outcomes was undertaken alongside the PD COMM pilot trial involving three 
arms: LSVT® LOUD treatment (n = 30); standard NHS SLT (n = 30); and a control arm (n = 29) excluded from receiving 
therapy for at least 6 months after randomisation unless deemed medically necessary. For all trial arms, resource use 
and NHS, social care and patient costs and quality of life were collected prospectively at baseline, 3, 6, and 12 months. 
Total economic costs and outcomes (EQ-5D-3L, ICECAP-O) were considered over the 12-month follow-up period from 
an NHS payer perspective. Quality of life measures for economic evaluation of SLT for people with Parkinson’s disease 
were compared.
Results: Whilst there was no difference between arms in voice or quality of life outcomes at 12 months, there were 
indications of differences at 3 months in favour of SLT, which need to be confirmed in the main trial. The estimated 
mean cost of NHS care was £3288 per patient per year for the LSVT® LOUD arm, £2033 for NHS SLT, and £1788 for the 
control arm. EQ-5D-3L was more strongly correlated to voice impairment than ICECAP-O, and was sensitive to differ-
ences in voice impairment between arms.
Conclusions: The pilot did not identify an effect of SLT on disease-specific or economic outcomes for PwPD at 
12 months; however, there appeared to be improvements at 3 months. In addition to the sample size not powered 
to detect difference in cost-consequence analysis, many patients in the control arm started SLT during the 12-month 
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Key messages regarding feasibility
• There is a lack of published evidence on costs and 
cost-effectiveness of Speech and Language Therapy 
(SLT) in Parkinson’s disease and uncertainties regard-
ing economic outcome measures.
• Resource use data collection is feasible in this patient 
group, and differences in cost were mainly due to dif-
ferences in SLT costs. The economic evaluation for 
the main trial should also consider carer and patient-
incurred costs.
• The Euro-Qol EQ-5D-3L was both valid and sensi-
tive when considering voice impairment levels and 
changes in levels. The analysis shows that for the 
main trial, the most appropriate economic measure is 
EQ-5D-3L; however, ICECAP-O can also be used.
Background
Parkinson’s disease (PD) is a progressive neurological 
disease, which is estimated to affect 100–180 people per 
100,000 population [1]. PD is primarily a movement dis-
order, not only resulting in disability and impaired quality 
of life (QoL), but can also result in anxiety and depres-
sion, and impaired cognition [2]. The presentation of 
symptoms varies between individuals and through the 
course of the disease [2].
An estimated 70% of People with Parkinson’s disease 
(PwPD) in developed countries have a speech disorder 
[3], with the occurrence and severity of speech disor-
ders increasing with severity of PD [4]. Among PwPD, 
38% report speech among their top 4 concerns [3] and 
three-quarters report that their speech has deteriorated. 
PwPD’s perception of their own speech is not easily 
measured using self-assessed quality of life tools [5], and 
PwPD rate their speech as worse than their communica-
tion partners’ [6, 7].
Lee Silverman Voice Treatment (LSVT) is an estab-
lished SLT approach developed for PwPD, and works 
by encouraging participants to pay attention to speech 
outputs [8]. LSVT® LOUD is a commercially pat-
ented programme comprising of 16 60-min sessions of 
SLT delivered over 4  weeks [9]. An audit of Parkinson’s 
Disease services within the UK National Health Service 
(NHS), estimated that 80% of service providers offer a 
version of the intervention [10], although only 35% of 
services offer LSVT® LOUD to all patients assessed as 
requiring SLT for communication problems. The stand-
ard NHS SLT treatment is typically 6–8 weekly sessions, 
administered as per local practice by state-registered 
speech and language therapists and expected to typically 
involve one session of 45  min per week for 6–8  weeks 
of varying content as determined by patient need [11]. 
Systematic reviews [12, 13] have concluded that there is 
currently insufficient evidence on the clinical and cost 
effectiveness of LSVT® LOUD compared with standard 
SLT or no treatment. No studies have been identified 
which estimate the cost of SLT in PwPD. The PD COMM 
trial which is ongoing will address this gap by comparing 
the clinical effectiveness and cost-effectiveness between 
LSVT® LOUD, NHS SLT, and a control arm [14]. The 
PD COMM pilot trial was undertaken to assess the feasi-
bility and acceptability of a large-scale RCT [14].
The objectives of this economic analysis were to test 
data collection methods, compare cost and outcome data 
for the alternative interventions in the PD COMM pilot 
trial, and to consider the validity of alternative outcome 
measures for economic evaluation in the full trial.
Methods
Pilot trial
The methods and results of the pilot trial are reported 
in detail elsewhere [11, 14]. In brief, a randomised con-
trolled trial (RCT) design was used in which participants 
were randomised to receive one of three alternative 
treatments:
• LSVT® LOUD: Lee Silverman Voice Treatment
• NHS SLT: NHS speech and language therapy
• Control: No intervention in first 6  months, unless 
deemed medically necessary
People with idiopathic PD and self-reported problems 
with voice or speech who had not received SLT for PD 
speech-related problems in the last 2 years and who did 
not have dementia were approached in their normal 
period used for economic analysis, in line with the study protocol. The LSVT® LOUD intervention was more intense 
and therefore more costly. Early indications suggest that the preferred economic outcome measure for the full trial is 
EQ-5D-3L; however, the ICECAP-O should still be included to capture a broader measure of wellbeing.
Trial registration: International Standard Randomised Controlled Trial Number Register: ISRCTN75223808. Regis-
tered 22 March 2012.
Keywords: Parkinson’s disease, Pilot randomised controlled trial, Speech and language therapy, Cost-consequence 
analysis
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outpatient appointment. Following consent, participants 
completed a baseline assessment prior to randomisation. 
Participants and therapists were informed of the treat-
ment allocation, but assessors of the vocal assessments 
were blind to treatment allocation. Both NHS SLT and 
LSVT® LOUD were completed in community-based set-
tings (in some cases in the patient’s home) or in outpa-
tient neurology units. Information on resource use and 
outcomes was collected at baseline, and then at 3, 6, and 
12 months post-randomisation.
Economic analysis
A cost consequence analysis (CCA) was undertaken, 
analysing and presenting costs and outcomes separately 
[15]. This is in line with recommendations for the analy-
sis of pilot studies [16]. The costs and consequences were 
compared at 12 months for: LSVT® LOUD versus NHS 
SLT; NHS SLT versus control; and LSVT® LOUD versus 
control. The focus of the primary cost analysis was from 
an NHS perspective. Additional information on social 
care costs, private health care usage, and out of pocket 
expenditure was reported separately, but not as part of 
overall costs due to limited data. In line with the main 
analysis of the pilot study, a complete case analysis was 
undertaken [14]. Cases were excluded where there was 
missing resource use data at one or more time points. All 
analyses were undertaken using STATA 16.1.
Resource use
A micro-approach to costing was used covering: trial 
data on SLT delivered to LSVT® LOUD and NHS 
patients; estimates of set-up costs for LSVT® LOUD; and 
other NHS, residential, social services, and direct patient 
costs collected from a specifically designed resource use 
questionnaire completed by participants. Primary, com-
munity and outpatient health services were captured: 
information on inpatient care was not collected, due to 
limited relevance to the intervention. Medication was 
recorded at baseline and was assumed to be unchanged 
over the 12-month period. Whilst there may be small 
medication changes over 12 months, these are expected 
only to have a small effect on costs, and SLT interventions 
are expected to have minimal, if any, impact on medica-
tion. Resource use which was recorded by patients in the 
“other” subsections on the form was reallocated where 
possible to the relevant existing resource use categories. 
Except for GP and practice nurse visits, the location of 
NHS services was not recorded, and so other services 
were costed on the basis that they took place on NHS 
premises. Resource use was summarised for each arm 
and reported separately for privately funded services.
To ensure that any visits for SLT in addition to the trial 
were captured, visits for SLT were recorded on both the 
resource usage questionnaire by participants and as part 
of the session logs by speech and language therapists. 
These could be visits by patients in the control arm who 
may have started SLT after 6  months, in line with the 
protocol, or further SLT after the end of the interven-
tion by the intervention arms. Some participants also 
reported SLT visits as outpatient appointments. Resource 
use which double counted activity (between participants 
and therapist reported data, and between hospital and 
community visits reported by participants) was excluded. 
Trial sessions were costed based on recorded length of 
sessions. The mean session length for LSVT was 62 min 
(range 44–90  min) and 54  min for NHS SLT (range 
36–84 min). Non-trial additional visits were costed based 
on an average estimated session length of 60 min. Loca-
tion was recorded for trial sessions: speech and language 
therapists’ travel time for home visits was estimated to be 
1 h per visit.
LSVT® LOUD requires the speech and language ther-
apists to attend a specialised 2-day training course. The 
cost of training per participants treated was estimated 
using national data on SLT service delivery on the basis 
of cost of training per patient in a typical SLT (Supple-
mentary Table 1).
Unit costs of health and social care
Costs of care were estimated using national costing data 
[17] where available, or other appropriate sources [18] 
(Supplementary Table 2). The pricing year was 2014/15. 
Unit costs were multiplied by resource use to calculate 
costs for each trial arm. Medication costs were estimated 
from the British National Formulary [19–21] based on 
dose, quantity and formulation for PD-related drugs the 
participant was receiving at baseline.
Patient costs
Direct care costs were estimated for private services, 
using published data from relevant care providers [22] 
(Supplementary Table 2). Out of pocket travel and other 
costs reported by participants in the resource use ques-
tionnaire were summarised. Information on the impact 
of PD on participants and carers’ work and usual activi-
ties was not collected in detail, and there was no infor-
mation about previous work, so it was not possible to 
estimate productivity loss. Although patients may also 
contribute to social care costs, this split of costs was not 
available.
Outcomes
A number of validated outcome measures were used in 
the pilot [11, 14]. This analysis focuses on the economic 
measures EuroQoL EQ-5D-3L [23] and ICECAP-O [24], 
the summary index and communication domain score 
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for the Parkinson’s Disease Questionnaire-39 (PDQ-39) 
QoL measure [25], and the voice measure Voice Handi-
cap Index (VHI) [26]. EQ-5D-3L includes five questions 
addressing health-related QoL: mobility, self-care, usual 
activities, pain/discomfort, anxiety/depression [23], and 
was valued using UK weights [27]. ICECAP-O includes 
five questions covering the capability attributes: attach-
ment, security, role, enjoyment, control [24] and was 
valued using weights generated using best–worst scaling 
[28]. Differences between arms in the change in outcome 
measures between baseline and 3, 6, and 12 months were 
estimated using a linear regression model, adjusting for 
the baseline value of the outcome. Quality adjusted life 
year (QALY) differences at 12  months were calculated 
using the area under the curve method using QoL values 
at baseline, 3, 6, and 12 months, and adjusting for base-
line EQ-5D-3L score and duration of disease [29]. Par-
ticipants with missing outcome data were excluded and a 
complete case analysis was undertaken.
Analysis
Detailed analysis of costs was undertaken only for NHS 
costs, due to limited data collection and information on 
social care, private, and direct patient costs. NHS costs 
(with and without SLT) and SLT costs for each arm were 
estimated; bias-corrected bootstrapping (5000 replica-
tions) was undertaken to produce 95% confidence inter-
vals, allowing for potential skewness in the data [30]. 
Where there was a notable cost outlier, sensitivity analy-
sis was undertaken recalculating costs after removing 
that observation. The influence of baseline variables on 
cost was examined through a regression model, in order 
to robustly estimate the difference in cost between arms. 
Based on findings from economic burden studies of PD 
[31, 32], the variables considered for the linear regression 
model were duration of PD, baseline Parkinson’s-related 
QoL (PDQ-39 summary index), and Hoehn and Yahr 
(H&Y) severity score. Adjusted R2 values were compared 
to determine which variables were the strongest con-
tributors to the explanatory value of the model. A second 
model was also tested including baseline VHI, PDQ-39 
communication domain score and EQ-5D-3L utility at 
baseline. The difference between interventions was then 
estimated using bias-corrected bootstrapping to generate 
95% confidence intervals.
Validity analysis
An exploratory analysis of the validity of EQ-5D-3L 
and ICECAP-O for speech impairment in PD was also 
undertaken. Convergent validity of the EQ-5D-3L and 
ICECAP-O utility measures for PD and speech-related 
measures was assessed, using correlation analysis, to 
see if the measures converge with other measures as 
expected [33]. The analysis was conducted at baseline for 
all the participants in the pilot study to maximise the data 
available for analysis. Pearson’s correlation was used for 
correlations between summary scores, and Spearman’s 
rank for correlation between responses to individual 
questions. A correlation coefficient of 0.5 or more was 
considered strong, between 0.3 and less than 0.5 moder-
ate, and below 0.3 weak [34]. Differences in VHI, PDQ-
39, ICECAP-O score, and EQ-5D-3L at baseline were 
also compared to assess if outcome measures are able to 
discriminate between groups [33]. The groups used in 
this comparison were participants with less severe versus 
more severe PD, defined as a H&Y score of two or below 
versus 2.5 and above [35]; and participants reporting that 
speech impacted on their social activities versus other 
participants. The analyses were undertaken using t-tests 
with means and 95% confidence intervals presented.
Results
Baseline characteristics
Baseline characteristics of participants in each response 
arm are reported in Table 1: the LSVT® LOUD arm had 
longer average duration of PD, and were receiving higher 
therapy doses of medication, but severity of disease was 
not consistently higher.
Resource use
Use of NHS and social care resources by participants in 
each arm over 12  months was summarised for partici-
pants where resource use data was available at all three 
time points (Supplementary Table 3). Across all the treat-
ment arms the predominant services accessed by partici-
pants were primary care, outpatient services, and other 
therapists, particularly physiotherapists. Few participants 
reported receiving social care services. However, two 
Table 1 Baseline characteristics by treatment arm
a Collected as part of initial SLT assessment, so only available for LSVT and NHS 
SLT groups
Key characteristics LSVT NHS SLT Deferred
(n = 30) (n = 30) (n = 29)
Demographic
 Age, mean (SD) 67 (8.4) 68 (10.3) 65 (7.5)
 Gender: n (%) male 23 (77) 23 (77) 23 (79)
Clinical history
 Years since diagnosed, mean (SD) 6.1 (3.7) 5.6 (4.2) 4.9 (3.9)
 Severity (H&Y stage) 2.5 and above, 
n (%)
10 (34) 13 (44) 6 (20)
 Number of PD medications, mean 2.1 (1) 1.9 (1) 1.6 (0.9)
Perception of speecha: n (%)
 Patient perceives speech/voice 
problems
23 (82) 23 (79)
 Speech affects social activities 18 (64) 14 (48)
Page 5 of 11Scobie et al. Pilot Feasibility Stud           (2021) 7:154  
participants were in residential care (social care funded) 
for the duration of the study. Participants reported simi-
lar levels of resource use at 3, 6, and 12 months.
Resource use related to the intervention
Participants in the LSVT® LOUD arm had over twice as 
many sessions and SLT time (mean 14.4) as participants 
in the NHS SLT arm (mean 5.6), and both arms also 
received additional non-trial sessions (mean sessions 3.6 
for LSVT® LOUD and 1.6 for NHS SLT). Participants in 
the control arm received a mean of 5 SLT sessions over 
12 months, with 18 participants reporting receiving SLT 
in their 12  month resource use questionnaire. LSVT® 
LOUD patients who completed the first week of treat-
ment (4 sessions) finished the course. Two participants 
who had four or fewer sessions stopped treatment due to 
issues related to availability of staff. In the NHS arm, 29 
participants had at least one session and the sessions per 
patient reduced over time; 1 participant received more 
than 8 sessions.
Costs
Costs for each type of service were summarised for 
NHS and social care (Table  2) based on unit costs and 
resources used (Supplementary Table  2). Medication 
costs were significant and were higher in the LSVT® 
LOUD arm, and can be attributed to this arm presenting 
with more mean PD medications prescribed at baseline 
(Table  1). Further details of medication costs are pre-
sented in Supplementary Table  4. Other major areas of 
NHS cost were out-patient appointments, GPs and pri-
mary and community nursing services. In line with ser-
vice use, social care contributed little to the cost, with 
the exception of the two participants in residential care. 
Participants’ direct costs included travel (43 patients), 
medication (7 patients), use of private therapists, such 
as physiotherapists, and expenditure such as install-
ing a stair lift, tilt/riser chairs, and other equipment (16 
patients) (Supplementary Tables 5 and 6).
The mean NHS costs, with and without SLT, are shown 
in Table  3, with 95% CIs (based on 5000 bootstrapped 












Speech and language therapist (SLT)
 Set-up costs 18.6 – –
 SLT trial sessions 940 (340) 343 (232) –
 SLT travel 104 (265) 13 (64) –
 Additional SLT sessions 51 (147) 57 (123) 325 (389)
Sub-total 1113 (496) 413 (247) 325 (389)
Medication 883 (691) 616 (646) 577 (598)
Primary care and community nursing services
 GP surgery 165 (172) 166 (135) 143 (141)
 GP home 57 (236) 68 (160) 17 (48)
 Practice nurse 56 (54) 42 (59) 43 (58)
 Practice nurse home 6 (20) 7 (19) 5 (22)
 Parkinson’s disease nurse specialist 106 (87) 70 (76) 111 (58)
 Health visitor 15 (34) 4 (15) 4 (14)
Sub-total 405 (357) 358 (196) 323 (192)
Therapists and other healthcare professionals
 Social worker 16 (52) 10 (35) 0 (0)
 Physiotherapist 84 (144) 85 (171) 62 (82)
 Occupational therapist 31 (62) 22 (62) 13 (37)
 Other including home care 281 (1301) 53 (149) 16 (77)
Sub-total 412 (1289) 170 (270) 91 (122)
Outpatient appointments
 PD medical appointments 266 (231) 216 (222) 135 (139)
 PD other appointments 30 (87) 34 (89) 76 (168)
 Other appointments 197 (189) 235 (234) 211 (295)
Sub-total 492 (338) 486 (247) 422 (435)
 Social care services 26 (98) 137 (614) 0.4 (2)
 Residential care (/week) 0 (0) 4810 (16,296) 0 (0)
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replications). The SLT costs were similar between the 
NHS SLT and control arm, but substantially higher for 
the LSVT® LOUD arm. Excluding SLT, NHS costs were 
more similar across arms, although still higher for the 
LSVT® LOUD arm, as a result of higher medication and 
community service resource use. Removal of an outly-
ing observation from the LSVT® LOUD arm reduced the 
all-NHS services cost to £3071 (95%CI £2644–3533) and 
the NHS services excluding SLT costs to £1946 (95%CI 
£1504–2448), both still higher than the other arms.
Regression analysis indicated that duration of illness 
was the strongest confounding factor, with an increase 
of £133 per year since diagnosis of PD, adjusted for all 
other factors. Adjusting for illness duration, the NHS 
costs for the LSVT® LOUD arm were £948 higher than 
the NHS SLT arm and £1345 higher than the control 
arm (Table 4), similar to the cost of SLT for the LSVT® 
LOUD arm of £1113 (Table  2). The costs for the NHS 
SLT arm were £307 higher than the control arm (95% 
CI £736 to £132). An additional model was also tested 
including baseline VHI, EQ-5D-3L, and PDQ-39 com-
munication score (Table 4). Duration of illness was the 
strongest confounding factor for all comparisons; how-
ever, this had a much weaker influence on the NHS SLT 
vs. control comparison.
Outcomes
VHI scores were similar between arms at baseline, but 
the PDQ-39 summary index was higher in the LSVT® 
LOUD arm (indicating poorer QoL) (Table  5). Con-
sistent with this, the EQ-5D-3L score was lower in the 
LSVT® LOUD arm, and highest in the control arm; the 
reverse was the case for ICECAP-O although the scores 
are more similar between arms.
The VHI improved between baseline and 3  months 
for both the treatment arms, but this effect was only 
maintained at 6 and 12  months for patients in the 
LSVT® LOUD arm. The control arm showed worsen-
ing voice quality at 3  months, with improvements at 
12 months, at which time point over half of participants 
had received SLT. Communication related QoL using 
the PDQ-39 communication domain also improved for 
both treatment arms at 3 months. Differences between 
arms in change in outcome measures at 3, 6, and 
12  months, the end point for the economic analysis, 
are summarised in Table  6, adjusting for baseline val-
ues. There was no evidence of a difference in outcomes 
between arms at 12 months.
Quality adjusted life years (QALYs)
QALYs were calculated over the 12 months, for the 74 
patients with an EQ-5D-3L score at baseline, 3, 6, and 
12 months. Absolute unadjusted QALYs were 0.56 for 
the LSVT® LOUD arm and 0.63 for both the NHS SLT 
and control arms (Table 3). However, there were only 
minimal differences in total QALYs between treatment 
arms, after adjusting for baseline EQ-5D-3L score 
(Table 6).
Table 3 Cost estimate/per patient for NHS services, with and without SLT, and QALYs for each treatment arm (2014/15 costs)
£/patient (bootstrapped 95% CI) Unadjusted 
12-month 
QALYs
NHS services excl SLT SLT All NHS services Mean (SD)
LSVT (n = 24) 2175 (1631, 2875) 1113 (923 to 1310) 3288 (2776 to 3972) 0.56 (0.28)
NHS SLT (n = 24) 1620 (1326 to 1978) 413 (332 to 529) 2033 (1728 to 2379) 0.63 (0.21)
Control (n = 28) 1413 (1144 to 1726) 325 (195 to 478) 1738 (1450 to 2064) 0.63 (0.22)
Table 4 Cost differences between treatment arms
*  denotes reference group
Mean, £ 95% CI
Unadjusted analysis
 LSVT vs NHS SLT* (n = 48) 1256 (601, 1946)
 NHS SLT vs control* (n = 52) 294 (− 149, 727)
 LSVT vs control* (n = 52) 1550 (944, 2217)
Controlling for duration of illness
 LSVT vs NHS SLT* (n = 48) 948 (436, 1502)
 NHS SLT vs control* (n = 52) 307 (− 111, 748)
 LSVT vs control* (n = 52) 1345 (825, 1923)
Controlling for duration of illness and baseline VHI, EQ-5D-3L, and 
PDQ-39 communication scores
 LSVT vs NHS SLT* (n = 44) 1105 (587, 1678)
 NHS SLT vs control* (n = 47) 74 (− 341, 513)
 LSVT vs control* (n = 47) 1175 (626, 1775)









VHI 41.7 (34.3, 49.4) 42.2 (33.3, 51.9) 42.4 (34.8, 50.9)
PDQ39-COMM 35.3 (27.3, 44.1) 32.8 (25.8, 40.8) 33.3 (27.0, 41.4)
PDQ-39 summary 32.4 (26.8, 37.8) 28.1 (23.6, 33.2) 26.4 (21.7, 31.6)
EQ-5D-3L 0.59 (0.48, 0.69) 0.64 (0.56, 0.72) 0.72 (0.66, 0.78)
ICECAP-O 0.79 (0.74, 0.84) 0.78 (0.70, 0.83) 0.75 (0.66, 0.82)
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Validity of outcome measures for PwPD
There was strong correlation between the voice meas-
ures, and between PD-related QoL (summary index and 
communication score) and voice outcomes (Table  7). 
EQ-5D-3L was strongly correlated to PDQ-39, and 
moderately correlated to the voice measures. The ICE-
CAP-O measure was only weakly correlated with EQ-
5D-3L and VHI. ICECAP-O was weakly correlated with 
voice measures. Negative correlations were due to the 
health economic outcomes scoring high for better out-
comes and the PD-related scales scoring low for better 
outcomes.
Relationships between EQ-5D-3L and ICECAP-O 
dimensions were examined (Supplementary Table  7). 
Moderate correlations existed between ICECAP-O Con-
trol and EQ-5D-3L Mobility and Self-Care, suggesting 
similar constructs relating to independence and ability 
to do things without help. There were also moderate cor-
relations between ICECAP-O enjoyment and EQ-5D-3L 
mobility; and between ICECAP-O Security and EQ-
5D-3L Usual activities. The ICECAP-O attributes role 
and attachment had weak levels of correlation with the 
EQ-5D-3L dimensions, reflecting the different concepts 
they are measuring.
Table 6 Differences between treatment arms in voice, quality of life and QALYs at 3, 6, and 12 months, after adjusting for baseline 
values
VHI ranges from 0 to 120; PDQ-39 summary index and communication domain score range from 0 to 100, where low score is good. Positive difference favours 
treatment
EQ-5D-3L ranges from − 0.59 to 1; ICECAP-O from 0 to 1, where high score is good. Negative difference favours treatment
a  reference arm
Outcome LSVT® LOUDa vs NHS SLT estimate (95% 
CI)







2.0 (− 7.0, 10.9)
8.4 (− 0.6, 17.4)
6.7 (− 3.7, 17.1)
6.7 (− 1.0, 14.4)
3.6 (− 3.6, 10.7)
0.03 (− 9.2, 9.3)







3.6 (− 5.9, 13.2)
 − 0.06 (− 0.15, 0.04)
1.3 (− 10.4, 13.0)
4.5 (− 4.1, 13.7)
0.9 (− 8.2, 9.9)
1.4 (− 8.3, 11.1)
8.7 (− 1.1, 18.5)
6.6 (− 2.4, 15.6)





1.4 (− 4.0, 6.7)
3.9 (− 2.2, 10.1)
1.1 (− 5.3, 7.0)
3.3 (− 1.0, 7.7)
 − 0.2 (− 5.1, 4.7)
 − 3.1 (− 7.6, 1.5)
5.2 (− 0.1, 10.4)
4.4 (− 0.7, 9.4)





0.07 (− 0.03, 0.16)
0.05 (− 0.08, 0.17)
0.01 (− 0.14, 0.17)
 − 0.15 (− 0.36, − 0.26)
 − 0.04 (− 0.15, 0.06)
 − 0.04 (− 0.17, 0.94)
 − 0.09 (− 0.21, 0.04)
 − 0.00 (− 0.12, 0.12)





 − 0.01 (− 0.8, 0.06)
 − 0.05 (− 0.16, 0.05)
 − 0.06 (− 0.15, 0.04)
0.02 (− 0.05, 0.09)
0.08 (− 0.02, 0.17)
0.08 (− 0.01, 0.17)
0.01 (− 0.07, 0.09)
0.02 (− 0.11, 0.07)
0.01 (− 0.07, 0.09)
Total QALYs 0.03 (− 0.05, 0.10)  − 0.06 (− 0.15, 0.02)  − 0.04 (− 0.12, 0.05)
Table 7 Convergence between baseline outcome measures (Pearson’s correlation coefficient)
VHI ranges from 0 to 120 where low score is good; PDQ-39 summary index and communication domain score range from 0 to 100, where low score is good
EQ-5D-3L ranges from − 0.59 to 1; ICECAP-O from 0 to 1, where high score is good
PDQ-39 EQ-5D-3L ICECAP-O VHI VR-QoL PDQ_ COMM
PDQ-39 Summary 1
EQ-5D-3L  − 0.65 1
ICECAP-O  − 0.24 0.20 1
VHI 0.61  − 0.38  − 0.19 1
VR-QoL 0.57  − 0.39  − 0.27 0.87 1
PDQ_COMM 0.73  − 0.42  − 0.31 0.73 0.76 1
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The relationship between the dimensions of PDQ-39 
and the economic measures EQ-5D-3L and ICECAP-O 
were explored (Supplementary Tables 8 and 9). PDQ-39 
and EQ-5D-3L dimensions relating to similar constructs 
are strongly correlated, for example ADL and self-care. 
ICECAP-O and PDQ-39 dimensions were generally more 
weakly correlated.
The group comparisons (Table  8) assessed whether 
the outcome measures are able to distinguish between 
known patient groups based on each of the two variables 
(severity, and patient perception of speech impairment). 
Participants with more severe PD had significantly 
lower EQ-5D-3L scores, and worse PDQ-39 summary 
and communication scores, but there was no evidence 
of a difference in ICECAP-O, although a weak relation-
ship was seen with VHI. Participants who reported that 
speech impacted on their social activities had much 
higher (worse) scores on VHI and PDQ-39 summary 
index and communication domain score, but there was 




This was an exploratory economic evaluation alongside 
a pilot RCT comparing costs and outcomes of LSVT® 
LOUD, NHS SLT, and no treatment at 12  months. The 
LSVT® LOUD arm received more intensive SLT over 
a longer period than the NHS SLT arm. Between 6 and 
12 months, 18 patients in the control arm received SLT, 
and over the 12  months received only a slightly lower 
number of sessions that the NHS SLT arm. There was 
no evidence of a difference in outcomes at 12  months, 
although some evidence of improvement in voice 
outcomes at 3  months. NHS costs were £3288 for the 
LSVT® LOUD arm, £2033 for the NHS SLT arm and 
£1738 for the control arm. Differences in cost were 
largely accounted for by differences in SLT costs. Other 
costs were similar between trial arms and comparable to 
those reported in other studies with patients of similar 
severity of PD [31, 36].
Regarding validity of outcome measures, EQ-5D-3L 
was more strongly related to voice impairment than ICE-
CAP-O, and was sensitive to differences in voice impair-
ment in patients. This could be because voice impairment 
is related to overall PD severity and other PD related 
impairment, which is captured well by EQ-5D-3L. EQ-
5D-3L and PDQ39 captured similar health constructs 
in four dimensions: mobility, pain/discomfort, anxiety/
emotional wellbeing, and self-care/ADL. The instru-
ments showed strong correlations for these dimensions, 
and both instruments also showed worse scores for 
patients with more severe PD [37]. ICECAP-O was more 
weakly correlated with PDQ-39 than EQ-5D-3L, and 
ICECAP-O attributes were correlated with the PDQ-39 
dimensions Stigma, Communication and Emotional well-
being. This suggests that ICECAP-O is aligned to differ-
ent constructs to EQ-5D-3L [38], and the measures are 
complementary.
Strengths
The PD COMM Pilot is the first study to examine the 
economic aspects of speech and voice difficulties in PD, 
a difficult area for research, given that speech is one of a 
wide range of health aspects affected by PD, for which it 
is not clear which aspects of costs should be considered. 
The resource use questionnaire captured NHS costs in 
detail, allowing a detailed analysis of resource use as part 
of a cost consequence analysis. Collection of informa-
tion on SLT visits directly from patients was valuable as 
it quantified the SLT received by the control arm. Care 
was taken to ensure that SLT was not double counted, 
by screening the patient completed resource question-
naire to remove SLT related to the trial. Further, the study 
includes a wide range of outcomes, relating to speech, 
PD, HRQoL, and capability, allowing analysis of the valid-
ity of outcome measures for SLT in PD, an area where 
there is currently a gap in research evidence.
Limitations
In this pragmatic trial, patients in the control arm 
received an average of 5 SLT sessions over the 12 months 
of the study, thus diluting the comparison between the 
LSVT® LOUD and NHS SLT arms. This impacted on the 
economic evaluation, which has a 12-month time hori-
zon. This has been addressed in the main trial protocol 
Table 8 Group comparisons: sensitivity of outcome measures to 
differences between patient groups at baseline
Voice Handicap Index (VHI) ranges from 0 to 120; PDQ-39 summary index and 
communication domain score range from 0 to 100, where low score is good
EQ-5D-3L ranges from -0.59 to 1; ICECAP-O from 0 to 1, where high score is good
a Reference group: H&Y 2.5 and above
b Reference group: yes response








VHI 8.8 (− 1.7, 19.4) 28 (17, 38)*
PDQ-39 Summary 10.1 (3.7, 16.6)* 14.9 (7.8, 21.9)*
PDQ_COMM 14.1 (4.7, 23.6)* 21.7 (10.9, 32.4)*
EQ-5D-3L  − 0.20 (− 0.31, − 0.10)*  − 0.11 (− 0.25, 0.04)
ICECAP-O  − 0.01 (− 0.1, 0.08)  − 0.02 (− 0.11, 0.07)
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[39] for which participants in the control arm have SLT 
deferred for at least 12 months, unless deemed clinically 
necessary.
This analysis was undertaken using data from a pilot 
study, and as such, the results are preliminary as they are 
based on a sample size not powered to detect difference 
in cost-consequence analysis, and using data collection 
methods which were being tested. There were differ-
ences between the participants in the study at baseline 
in duration of disease, and in PDQ39 and EQ-5D-3L 
scores. While response rates overall were high, the cumu-
lative impact of missing data meant that complete cases 
were available for analysis of resource use data for 85% 
of cases. Outcomes data was less complete, particularly 
for the voice measures. Multiple imputation was not 
undertaken, in line with the main analysis of the pilot 
study [14]. Given the insufficient sample size for a cost-
consequence analysis and missing data, findings from the 
analysis should be treated with caution.
There were some limitations in the data available for 
costing NHS services. Coding of the free text responses 
was needed to categorise outpatient activity, and 
also resource use reported under “other” by patients. 
Resource use in the last follow-up period may have been 
under reported by patients, as resources used were simi-
lar for this 6-month period to the earlier 3-month peri-
ods. Although bootstrapping of costs was undertaken to 
allow for skewed data, there was one notable outlier on 
resource use in the LSVT® LOUD arm for which sen-
sitivity analysis was undertaken. A full assessment of 
NHS costs was not undertaken, as inpatient costs and 
non-PD-related medication costs were not captured. 
The resource use questionnaire did not enable patients 
to report which social care costs were self-funded. Given 
the shifting landscape of social care costs [40], this is a 
limitation.
Regarding the analysis of outcomes, it should also be 
noted that the distribution of ICECAP-O and EQ-5D-3L 
scores at baseline was skewed, and so some caution is 
needed in interpreting the correlation between scores. 
Furthermore, Spearman’s rank correlation was used to 
compare dimension scores between outcome measures; 
however, the method assumes both measures are con-
tinuous. This is not the case for measures such as the EQ-
5D-3L and ICECAP-O which are categorical with three 
and four levels respectively.
Implications for economic analysis of full trial
Based on the preliminary analysis of outcome meas-
ures, the most appropriate economic measure appears 
to be EQ-5D-3L, as this was sensitive to differences 
in voice impairment. ICECAP-O is recommended as 
an additional economic measure, and analysis of the 
full trial data will allow the opportunity to compare 
ICECAP-O and EQ-5D-3L longitudinally, as recom-
mended by Mitchell [41]. It would be informative to 
analyse the relationship of the individual attributes 
of ICECAP-O with voice measures and to compare 
patient reported and clinically assessed voice meas-
ures, in relation to severity of PD, as the relationship 
between patient’s perception and clinical measures is 
unclear [3]. Further, given that the LSVT® LOUD is 
an intensive programme for which burden of treat-
ment is an important consideration [42], it would be 
interesting to further understand the relationship 
between severity and participation in treatment: PD 
patients have a wide range of symptoms and impair-
ments and there may be trade-offs in which symptoms 
are a priority to address from the patient’s perspective. 
A wider cost–benefit approach could be considered for 
this [43], taking account of patient and carer time in 
undertaking treatment, as well as NHS costs, and also 
carer outcomes [44].
Conclusions
The cost consequence analysis provides a detailed 
analysis of costs of PD for a community sample, and 
established the costs of LSVT® LOUD and NHS SLT. EQ-
5D-3L was more strongly related to voice impairment 
than ICECAP-O and was sensitive to differences in voice 
impairment in patients. Hence, the preferred economic 
outcome measure for the full trial is EQ-5D-3L, although 
it is recommended that ICECAP-O is also included, 
as there is evidence that this captures some important 
dimensions of PD related QoL which are not included in 
EQ-5D-3L.
The full trial will enable a more conclusive assessment 
of the effectiveness and cost-effectiveness of SLT for 
PwPD from an NHS perspective. Alternative perspectives 
for economic evaluation could also be considered, for 
example considering carer outcomes and patient costs. 
Further, the full trial will also provide the opportunity to 
assess with a larger sample which economic measure are 
sensitive to communication and voice impairment, the 
relationship with severity of PD, and the contribution of 
communication factors to overall QoL.
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